In vitro activity of axazaphosphorines in childhood acute leukemia: preliminary report

• Autorzy: Styczynski J. , Wysocki M. , Debski R. , Balwierz W. , Rokicka-Milewska R. , Matysiak M. , Balcerska A. , Kowalczyk J. , Wachowiak J. , Sonta-Jakimczyk D. , Chybicka A.
• Języki publikacji: EN

Abstrakty

EN

Glufosfamide (β-D-glucosyHfosfamide mustard) is a new agent for cancer chemo­therapy. Its pharmacology is similar to commonly used oxazaphosphorines, but it does not require activation by hepatic cytochrome P-450 and preclinically demon­strates lower nephrotoxicity and myelosuppression than ifosfamide. The aim of the study was a comparison of the drug resistance profiles of glufosfamide and other oxazaphosphorines in childhood acute leukemias. Leukemic cells, taken from chil­dren with ALL on diagnosis (n = 41), ALL on relapse (n = 12) and AML on diagnosis (n = 13) were analyzed by means of the MTT assay. The following drugs were tested: glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and mafosfamide cyclohexylamine salt (MAF). In the group of initial ALL samples median cytotoxicity values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8,«M, re­spectively. In comparison with initial ALL samples, the relative resistance for GLU and IFO in relapsed ALL samples was 1.9 (p = 0.049) and 1.3 (ns), and in initial AML samples 31 (p < 0.001) and 5 (p = 0.001), respectively. All oxazaphosphorines pre­sented highly significant cross-resistance. Glufosfamide presented high activity against lymphoblasts both on diagnosis and on relapse.

Słowa kluczowe

EN

chemotherapy; oxazaphosphorine; leukemia; childhood; in vitro; cancer

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2002
• Tom: 49
• Numer: 1
• Opis fizyczny: p.221-225,fig.

Twórcy

autor

Styczynski J.

• Medical University, Bydgoszcz, Poland

autor

Wysocki M.

autor

Debski R.

autor

Balwierz W.

autor

Rokicka-Milewska R.

autor

Matysiak M.

autor

Balcerska A.

autor

Kowalczyk J.

autor

Wachowiak J.

autor

Sonta-Jakimczyk D.

autor

Chybicka A.

Bibliografia

• 1.Brock, N., Hilgard, P., Peukert, M., Pohl, J. & Sindermann, H. (1988) Basis and new develop­ments in the field of oxazaphosphorines. Can­cer Invest. 6, 513-532.
• 2.Hilgard, P. & Pohl, J. (1986) Short communi­cation: Cause and prevention of mafosfa- mide-induced venous pain. Invest. New Drugs 4, 373-376.
• 3.Niemeyer, U., Engel, J., Hilgard, P., Peukert, M., Pohl, J. & Sindermann, H. (1989) Mafosfa­mide — a derivative of 4-hydroxycyclophos- phamide. Prog. Clin. Biochem. Med. 9, 35-60.
• 4.Pohl, J., Bertram, B., Hilgard, P., Nowrousian, M.R., Stuben, J. & Wiessler, M. (1995) D-19575 — a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother. Pharmacol. 35, 364-370.
• 5.Stuben, J., Port, R., Bertram, B., Bollow, U., Hull, W.E., Schaper, M., Pohl, J. & Wiessler, M. (1996) Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mus­tard and its effects on the incorporation of [methyl-3^]-thymidine in various tissues of the rat. Cancer Chemother. Pharmacol. 38, 355-365.
• 6.Veyhl, M., Wagner, K., Volk, C., Gorboulev, V., Baumgarten, K., Weber, W.M., Schaper, M., Bertram, B., Wiessler, M. & Koepsell, H. (1998) Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mus­tard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc. Natl. Acad. Sci. U.S.A. 95, 2914-2919.
• 7.Seker, H., Bertram, B., Burkle, A., Kaina, B., Pohl, J., Koepsell, H. & Wiesser, M. (2000) Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br. J. Cancer 82, 629-634.
• 8.Styczyński, J., Pieters, R., Huismans, D.R., Schuurhuis, G.J., Wysocki, M. & Veerman, A.J.P. (2000) In vitro drug resistance profiles in adult versus childhood acute lymphoblastic leukemia. Br. J. Haematol. 110, 813-818.
• 9.Makrynikola, V., Kabral, A. & Bradstock, K.F. (1991) Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: Significance for ex vivo purging of bone marrow for autologous transplantation. Bone Marrow Transplant. 8, 351-355.